Eyewire News

Featured Story

05.29.2026

Oculis Does Not Meet Primary Endpoint in Phase 3 DIAMOND Program of OCS-01 in DME

Key Takeaways OCS-01 eye drops for the treatment of DME failed to meet the primary endpoint of improving best corrected visual acuity (BCVA) at Week 52 in both phase 3 DIAMOND-1 and DIAMOND-2 trials OCS-01 demonstrated substantial and sustained reductions in retinal thickness versus vehicle across both studies Based on the phase 3 results, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME Oculis' OCS-01 eye drops for the treatment of diabetic macular edema (DME) failed to meet the primary endpoint in two phase 3 trials. The company announced topline results on Friday from its phase 3 DIAMOND-1 and DIAMOND-2 clinical trials evaluating OCS-01.

Read Story

Latest News Stories

05.29.2026

Study Finds Atopic Dermatitis May Raise Risk of Retinal Detachment

05.29.2026

Samsung Bioepis Launches Opuviz Aflibercept Biosimilar Across Europe

Therini Bio Doses First Patients in Phase 1b Trial of THN391 for DME image

05.28.2026

Therini Bio Doses First Patients in Phase 1b Trial of THN391 for DME

Maculaser Secures New Investment to Advance Temperature-Controlled Retinal Laser Therapy in Europe image

05.28.2026

Maculaser Secures New Investment to Advance Temperature-Controlled Retinal Laser Therapy in Europe

05.27.2026

Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Retinal Therapy

Cure Blindness Project Releases 2025 Impact Report Highlighting Global Reach and Restored Vision image

05.27.2026

Cure Blindness Project Releases 2025 Impact Report Highlighting Global Reach and Restored Vision

Outlook Therapeutics Wins FDA Appeal for Lytenava, Plans BLA Resubmission in June image

05.26.2026

Outlook Therapeutics Wins FDA Appeal for Lytenava, Plans BLA Resubmission in June

Oculus Launches AI-Assisted Tool to Improve Meibomian Gland Dysfunction Diagnostics image

05.26.2026

Oculus Launches AI-Assisted Tool to Improve Meibomian Gland Dysfunction Diagnostics

05.26.2026

Researchers in Japan Link Drinking Habits to Faster Progression of Presbyopia

Hoya Vision Care Highlights Myopia Management Innovation and Clinical Education at EAOO 2026 image

05.26.2026

Hoya Vision Care Highlights Myopia Management Innovation and Clinical Education at EAOO 2026

CooperVision to Spotlight New Clinical Research at BCLA Asia 2026 image

05.26.2026

CooperVision to Spotlight New Clinical Research at BCLA Asia 2026

ViaLase Launches First Commercial FLIGHT Procedures in Europe image

05.26.2026

ViaLase Announces First Commercial FLIGHT Procedures in Europe

Zeiss Appoints Bronwyn Brophy O’Connor as Head of Medical Technology Segment and CEO of Carl Zeiss Meditec image

05.22.2026

Zeiss Appoints Bronwyn Brophy O’Connor as Head of Medical Technology Segment and CEO of Carl Zeiss Meditec

Ingenia Therapeutics Receives Approval to Advance IPO in Korea image

05.22.2026

Ingenia Therapeutics Receives Approval to Advance IPO in Korea

05.22.2026

IQity and Sightpath Medical Announce Strategic Partnership

05.21.2026

Study Finds AI Shows Promise in Predicting Glaucoma Progression, but Clinical Gaps Remain

05.21.2026

Lexitas Pharma Services Acquires Erie Retina Research, CASExERIE, and Element Erie Assets

05.19.2026

Aflibercept Biosimilars Ahzantive and Baiama Now Available in the European Union

Becton, Dickinson and Company Names Peter Menziuso EVP and President, BD Interventional image

05.19.2026

Becton, Dickinson and Company Names Peter Menziuso EVP and President, BD Interventional

View More